Human medicines European public assessment report (EPAR): Segluromet, ertugliflozin,metformin hydrochloride, Date of authorisation: 23/03/2018, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Invanz, ertapenem, Date of authorisation: 18/04/2002, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR): Obizur, susoctocog alfa, Date of authorisation: 11/11/2015, Revision: 13, Status: Authorised

PRIME: priority medicines

Human medicines European public assessment report (EPAR): Yervoy, ipilimumab, Date of authorisation: 13/07/2011, Revision: 59, Status: Authorised

List of medicines currently in PRIME scheme

Recommendations on eligibility to PRIME scheme adopted at the CHMP meeting of 10-13 November 2025

Human medicines European public assessment report (EPAR): Vimpat, lacosamide, Date of authorisation: 29/08/2008, Revision: 56, Status: Authorised

Human medicines European public assessment report (EPAR): Opdivo, nivolumab, Date of authorisation: 19/06/2015, Revision: 68, Status: Authorised

Quarterly System Demo - Q4 2025, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 16 December 2025, 09:30 (CET) to 16 December 2025, 12:30 (CET)